We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome (MEPOCHUSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00716651
Recruitment Status : Completed
First Posted : July 16, 2008
Last Update Posted : June 15, 2012
Information provided by (Responsible Party):
Moosig, University Hospital Schleswig-Holstein

Brief Summary:

Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively in patients with asthma and which is characterized by prominent blood and tissue eosinophilia. The disease has a chronic smoldering course with a permanent need for medium to high corticosteroid doses. Available unselective immunosuppressive agents are often insufficient to reduce corticosteroid doses, to induce complete remission and to protect patients from disease flares which occur in more than 50 % of cases.

Interleukin-5 is the most potent cytokine regulating the production of eosinophil granulocytes which are the major effector cells in Churg-Strauss syndrome. Recently, an increased production of interleukin-5 was demonstrated in Churg-Strauss syndrome. Mepolizumab is a monoclonal IgG antibody targeting interleukin-5 and is effective in the treatment of the HES. The hypothesis of this study is, that mepolizumab will induce remission and allow for steroid reduction.

Condition or disease Intervention/treatment Phase
Churg Strauss Syndrome Drug: mepolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome
Study Start Date : July 2008
Actual Primary Completion Date : July 2010

Intervention Details:
  • Drug: mepolizumab
    750 mg mepolizumab iv q4wk until week 32

Primary Outcome Measures :
  1. Primary endpoint is the percentage of patients with Churg-Strauss Syndrome that attain remission [ Time Frame: 52 weeks ]

Secondary Outcome Measures :
  1. Change in BVAS score [ Time Frame: 52 weeks ]
  2. Change in Disease Extent Index score [ Time Frame: 52 weeks ]
  3. Permanent End organ damage assessed by the Vasculitis Damage Index [ Time Frame: 52 weeks ]
  4. Time to remission [ Time Frame: 52 weeks ]
  5. Response, defined as a 50 % reduction of the BVAS score [ Time Frame: 52 weeks ]
  6. Time to response [ Time Frame: 52 weeks ]
  7. The frequency of relapses [ Time Frame: 52 weeks ]
  8. Blood eosinophil count [ Time Frame: 52 weeks ]
  9. Frequency of all AEs and SAEs [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • informed consent
  • documented history of Churg Strauss Syndrome
  • active disease
  • subjects must complete screening and baseline assessment
  • stable corticosteroid dose of > 12.5 mg prednisolone for at least one week
  • treatment with cyclophosphamide (pulse or daily oral) or methotrexate or azathioprin or leflunomide in a stable dose for at least 4 weeks
  • not pregnant or nursing
  • negative pregnancy test and agree to practice birth control

Exclusion Criteria:

  • life threatening disease or other critical illness deemed inappropriate for inclusion in the study by the principal investigator
  • treatment with other immunosuppressive agents within 4 weeks prior to randomisation
  • corticosteroid pulse of > 60 mg within the last three weeks prior to randomisation
  • known secondary cause of eosinophilia
  • no history or clinical features of vasculitis
  • diagnosis of other primary systemic vasculitis
  • currently active malignant disease
  • abnormal laboratory values
  • impaired cardiac function
  • history of allergic reaction due to monoclonal antibodies
  • prior treatment with anti-hIL-5 monoclonal antibody
  • exposure to investigational drug within 30 days prior to randomisation
  • positive pregnancy test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00716651

Layout table for location information
University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd
Bad Bramstedt, SH, Germany, 24576
Sponsors and Collaborators
University Hospital Schleswig-Holstein
Layout table for additonal information
Responsible Party: Moosig, PD Dr. Frank Moosig, University Hospital Schleswig-Holstein
ClinicalTrials.gov Identifier: NCT00716651    
Other Study ID Numbers: RBB1
EudraCT 2006-001791-20
First Posted: July 16, 2008    Key Record Dates
Last Update Posted: June 15, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Churg-Strauss Syndrome
Pathologic Processes
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Vascular Diseases
Cardiovascular Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Autoimmune Diseases
Immune System Diseases